$2.15 Billion is the total value of Cormorant Asset Management, LP's 73 reported holdings in Q1 2020. The portfolio turnover from Q4 2019 to Q1 2020 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MRTX | MIRATI THERAPEUTICS INCcall | $38,435,000 | -40.3% | 500,000 | 0.0% | 1.79% | -30.5% | |
| RETA | REATA PHARMACEUTICALS INCcall | $36,085,000 | -29.4% | 250,000 | 0.0% | 1.68% | -17.8% | |
| MYOK | MYOKARDIA INC | $32,816,000 | -35.7% | 700,000 | 0.0% | 1.52% | -25.1% | |
| ZYME | ZYMEWORKS INC | $24,829,000 | -22.0% | 700,000 | 0.0% | 1.15% | -9.1% | |
| TWST | TWIST BIOSCIENCE CORP | $21,013,000 | +45.6% | 687,149 | 0.0% | 0.98% | +69.4% | |
| AVRO | AVROBIO INC | $4,942,000 | -22.7% | 317,579 | 0.0% | 0.23% | -9.8% | |
| NERV | MINERVA NEUROSCIENCES INC | $3,660,000 | -15.3% | 607,903 | 0.0% | 0.17% | -1.2% | |
| AUTL | AUTOLUS THERAPEUTICS PLCspon ads | $2,875,000 | -54.6% | 479,988 | 0.0% | 0.13% | -47.0% | |
| OTLKW | OUTLOOK THERAPEUTICS INC*w exp 02/18/202 | $65,000 | +140.7% | 416,666 | 0.0% | 0.00% | +200.0% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| QUOTIENT LTD | 30 | Q3 2021 | 4.3% |
| ASCENDIS PHARMA A/S | 30 | Q4 2022 | 4.8% |
| MINERVA NEUROSCIENCES INC | 29 | Q3 2021 | 4.4% |
| ACCELERON PHARMA INC | 28 | Q2 2021 | 3.4% |
| OMEROS CORP | 27 | Q3 2021 | 6.5% |
| MIRATI THERAPEUTICS INC | 25 | Q4 2022 | 7.6% |
| BLUEPRINT MEDICINES CORP | 25 | Q3 2021 | 3.6% |
| APELLIS PHARMACEUTICALS INC | 24 | Q3 2023 | 8.6% |
| NEUROCRINE BIOSCIENCES INC | 24 | Q1 2020 | 4.6% |
| ROCKET PHARMACEUTICALS, INC | 23 | Q3 2023 | 2.4% |
View Cormorant Asset Management, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Ambrx Biopharma Inc. | March 13, 2023 | 42,771,365 | - |
| Altimmune, Inc. | February 14, 2023 | 2,600,000 | - |
| Arcellx, Inc. | February 14, 2023 | 2,075,000 | - |
| BioAtla, Inc. | February 14, 2023 | 2,499,250 | - |
| Eledon Pharmaceuticals, Inc. | February 14, 2023 | 1,391,663 | - |
| GreenLight Biosciences Holdings, PBC | February 14, 2023 | 4,751,020 | - |
| Prometheus Biosciences, Inc. | February 14, 2023 | 700,000 | - |
| Tango Therapeutics, Inc. | February 14, 2023 | 1,000,000 | - |
| VectivBio Holding AG | February 14, 2023 | 1,515,087 | - |
| Viridian Therapeutics, Inc.\DE | February 14, 2023 | 1,100,000 | - |
View Cormorant Asset Management, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-05-08 |
| SC 13G | 2024-04-29 |
| 4 | 2024-04-22 |
| SC 13G/A | 2024-04-15 |
| 4 | 2024-04-03 |
| SC 13G | 2024-03-21 |
| 4 | 2024-03-18 |
| SC 13G/A | 2024-03-18 |
| 4 | 2024-03-11 |
| 13F-HR | 2024-02-14 |
View Cormorant Asset Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.